MYGN Myriad Genetics (MYGN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0000899923
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
120
13F, latest reported quarter
What the filings say about MYGN
Insiders, 180 days
-$39.2K net sold
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Myriad Genetics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, MYRIAD GENETICS INC insiders sold a net $39.2K of stock across 59 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 19, 2024.
- The trade is 8.7% of the 171,889 shares held after it.
- No other insider sold within 30 days.
- 120 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kumar Rashmi sold about $66.9K of MYGN on Jun 8, 2026, the largest insider sale at the company since 2024; 120 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 7.7% of the 97,441 shares held after it.
- No other insider bought within 30 days.
- 120 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bisaro Paul bought about $27.7K of MYGN on May 14, 2026; 120 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 8.1% of the 493,104 shares held after it.
- 1 other insider bought within 30 days.
- 120 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Raha Samraat S. bought about $200.0K of MYGN on Mar 9, 2026; 1 other insider bought within 30 days and 120 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Feb 26, 2026.
- -19.3% median (-19.3% mean) 90-day return after 2 previous buys.
- The trade is 17.0% of the 281,951 shares held after it.
- 1 other insider bought within 30 days.
- 120 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Phanstiel S. Louise bought about $223.7K of MYGN on Feb 27, 2026; 1 other insider bought within 30 days and 120 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Feb 25, 2026.
- The trade is 21.5% of the 233,951 shares held after it.
- 1 other insider bought within 30 days.
- 120 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Phanstiel S. Louise bought about $242.0K of MYGN on Feb 26, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 120 funds added in the latest 13F quarter.59 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$39.2K over 180 days
more than 58% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
120 funds bought in last quarter
more than 75% of Pharma & Biotech
Revenue
-1.6% year over year
below 59% of Pharma & Biotech
Margin
-44.4% net margin
more than 51% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
10.8% of the float short (float per yahoo 2026-10-26) · 4.2 days to cover · settled 2026-09-30
more than 67% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch MYGN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-25.2%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MYGN: institutional holders (13F)
13F holdings, latest reported quarter
10,890,440 sh
$62.2M
6,620,372 sh
$37.8M
5,735,000 sh
$32.7M
4,985,060 sh
$28.5M
4,582,083 sh
$26.2M
Congress trades in MYGN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MYGN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
MYGN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Federated Hermes MDT Small Cap Value Fund f/k/a Federated Hermes Clover Small Value Fund
$829.2K position · as of 2026-06-30
0.5%
Invesco NASDAQ Future Gen 200 ETF
$66.1K position · as of 2026-05-31
0.3%
Global X Genomics & Biotechnology ETF
$194.4K position · as of 2026-05-31
0.3%
Federated Hermes MDT Small Cap Core ETF
$841.1K position · as of 2026-05-31
0.3%
NVIT Small Cap Value Fund
$553.0K position · as of 2026-06-30
0.2%
VANGUARD MARKET NEUTRAL FUND
$1.4M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Samraat S. Raha
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$13.6M
$7.2M
$3.5M
-31%
-7%
2023
$12.1M
$14.2M
$4.1M
-3%
-6%
2022
$11.4M
-$4.5M
$2.7M
-27%
-10%
2021
$12.8M
$29.8M
$2.5M
+40%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $39.2K sold by insiders over 180 days, 120 funds added last quarter. Each figure is a federal filing, dated the day it went public.
MYGN financials
Revenue growth
-1.6%
XBRL, annual
Net margin
-44.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$806.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MYGN
| FY Dec 2025 | $824.5M |
| FY Dec 2024 | $837.6M |
| FY Dec 2023 | $753.2M |
| FY Dec 2022 | $678.4M |
| FY Dec 2021 | $690.6M |
| Jun 2026 | $190.7M |
| Mar 2026 | $200.4M |
| Dec 2025 | $209.8M |
| Sep 2025 | $205.7M |
| Jun 2025 | $213.1M |
| Mar 2025 | $195.9M |
| Dec 2024 | $210.6M |
| Sep 2024 | $213.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-14.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MYGN
| FY Dec 2025 | -44.4% |
| FY Dec 2024 | -15.2% |
| FY Dec 2023 | -34.9% |
| FY Dec 2022 | -16.5% |
| FY Dec 2021 | -3.9% |
| Jun 2026 | -22.7% |
| Mar 2026 | -17.0% |
| Dec 2025 | -3.8% |
| Sep 2025 | -13.3% |
| Jun 2025 | -155.1% |
| Mar 2025 | -0.1% |
| Dec 2024 | -20.0% |
| Sep 2024 | -10.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$7.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MYGN
| FY Dec 2025 | -$13.8M |
| FY Dec 2024 | -$27.7M |
| FY Dec 2023 | -$174.1M |
| FY Dec 2022 | -$151.6M |
| FY Dec 2021 | $600.0K |
| Jun 2026 | -$10.4M |
| Mar 2026 | -$21.1M |
| Dec 2025 | $5.9M |
| Sep 2025 | $18.3M |
| Jun 2025 | -$16.4M |
| Mar 2025 | -$21.6M |
| Dec 2024 | $3.0M |
| Sep 2024 | -$2.8M |
At each fiscal year end
Single quarter
Debt to equity
0.59x
long-term 2026-06-30 plus current 2025-06-30 (12 months older than the period end); equity 2026-06-30
Debt to equity MYGN
| FY Dec 2025 | 0.49x |
| FY Dec 2024 | 0.06x |
| FY Dec 2023 | 0.18x |
| FY Dec 2022 | 0.12x |
| FY Dec 2021 | 0.11x |
| Jun 2026 | 0.59x |
| Mar 2026 | 0.53x |
| Dec 2025 | 0.49x |
| Sep 2025 | 0.48x |
| Jun 2025 | 0.15x |
| Mar 2025 | 0.08x |
| Dec 2024 | 0.06x |
| Sep 2024 | 0.20x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.04x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-06-30 (12 months older than the period end)
Cash flow to debt MYGN
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | -0.22x |
| FY Dec 2023 | -0.78x |
| FY Dec 2022 | -1.02x |
| FY Dec 2021 | 0.18x |
| Jun 2026 | 0.04x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.01x |
| Sep 2025 | -0.01x |
| Jun 2025 | -0.38x |
| Mar 2025 | -0.11x |
| Dec 2024 | -0.22x |
| Sep 2024 | -0.49x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-32.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity MYGN
| FY Dec 2025 | -68.5% |
| FY Dec 2024 | -17.1% |
| FY Dec 2023 | -31.5% |
| FY Dec 2022 | -12.1% |
| FY Dec 2021 | -2.9% |
| Jun 2026 | -32.6% |
| Mar 2026 | -76.8% |
| Dec 2025 | -68.5% |
| Sep 2025 | -72.5% |
| Jun 2025 | -70.0% |
| Mar 2025 | -13.8% |
| Dec 2024 | -17.1% |
| Sep 2024 | -16.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-17.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MYGN
| FY Dec 2025 | -42.2% |
| FY Dec 2024 | -11.7% |
| FY Dec 2023 | -22.4% |
| FY Dec 2022 | -8.9% |
| FY Dec 2021 | -2.0% |
| Jun 2026 | -17.1% |
| Mar 2026 | -47.6% |
| Dec 2025 | -42.2% |
| Sep 2025 | -44.2% |
| Jun 2025 | -44.8% |
| Mar 2025 | -9.6% |
| Dec 2024 | -11.7% |
| Sep 2024 | -10.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital MYGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-20.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed MYGN
| FY Dec 2025 | -53.9% |
| FY Dec 2024 | -13.3% |
| FY Dec 2023 | -25.1% |
| FY Dec 2022 | -12.9% |
| FY Dec 2021 | -15.9% |
| Jun 2026 | -20.0% |
| Mar 2026 | -55.6% |
| Dec 2025 | -53.9% |
| Sep 2025 | -55.8% |
| Jun 2025 | -59.0% |
| Mar 2025 | -13.7% |
| Dec 2024 | -13.3% |
| Sep 2024 | -12.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MYGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$640.7M
market value at close 2026-10-26 on 2026-07-28 shares, plus long-term 2026-06-30 plus current 2025-06-30 (12 months older than the period end), minus cash 2026-06-30
Enterprise value MYGN
| FY Dec 2025 | $603.0M |
| FY Dec 2024 | $1.2B |
| FY Dec 2023 | $1.6B |
| FY Dec 2022 | $1.2B |
| FY Dec 2021 | $2.1B |
| Jun 2026 | $604.2M |
| Mar 2026 | $476.1M |
| Dec 2025 | $603.0M |
| Sep 2025 | $706.2M |
| Jun 2025 | $474.5M |
| Mar 2025 | $777.4M |
| Dec 2024 | $1.2B |
| Sep 2024 | $2.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-1.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield MYGN
| FY Dec 2025 | -2.4% |
| FY Dec 2024 | -2.2% |
| FY Dec 2023 | -11.1% |
| FY Dec 2022 | -12.9% |
| FY Dec 2021 | +0.0% |
| Jun 2026 | -1.4% |
| Mar 2026 | -3.2% |
| Dec 2025 | -2.4% |
| Sep 2025 | -2.5% |
| Jun 2025 | -7.7% |
| Mar 2025 | -3.0% |
| Dec 2024 | -2.2% |
| Sep 2024 | -3.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MYGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $824.5M | $837.6M | $753.2M | $678.4M |
| Gross profit | $576.6M | $585.4M | $517.0M | $476.4M |
| Operating income | -$387.2M | -$123.5M | -$257.4M | -$140.6M |
| Net income | -$366.0M | -$127.0M | -$263.0M | -$112.0M |
| EPS (diluted) | -3.95 | -1.41 | -3.18 | -1.39 |
| Operating cash flow | $1.8M | -$8.7M | -$110.9M | -$106.3M |
| Cash | $149.6M | $102.4M | $132.1M | $56.9M |
| Long-term debt | $119.9M | $39.6M | $38.5M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
MYGN Stock Sonar score 6/7 axes
Find similar shapesCompareMYGN ranks highest on institutional and government (75th percentile) and profitability (69th), and lowest on risk and compliance (33rd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MYGN filings, in plain words
Are Myriad Genetics insiders buying or selling MYGN?
In the 180 days to 2026-10-28, Myriad Genetics insiders were net sellers, a net $39.2K: $27.7K of purchases and $66.9K of sales reported on Form 4, by 1 buyer and 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Myriad Genetics insiders were net sellers of MYGN, a net $39.2K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
